Form 4: Personalis CMO Chen Acquires 15,000 Stock Options

Personalis, Inc.'s Chief Medical Officer, Richard Chen, acquired 15,000 stock options at an exercise price of $1.61 following a performance milestone.

Summary

• Richard Chen, Chief Medical Officer and Executive Vice President of Personalis, Inc. (PSNL), reported the acquisition of 15,000 derivative securities (stock options).
• The transaction date for this acquisition was February 23, 2026.
• The stock options have an exercise price of $1.61 per share.
• These options were granted on March 15, 2024, and vested upon the satisfaction of a specified reimbursement milestone.
• The options become exercisable on February 23, 2026, and expire on March 15, 2034.
• Following this transaction, Richard Chen beneficially owns 15,000 derivative securities.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event. While a routine compensation disclosure, the vesting of performance-based options indicates the achievement of a company milestone, which is generally favorable.

Positives

• The vesting of performance stock options indicates the satisfaction of a specified reimbursement milestone, suggesting positive operational progress for Personalis, Inc.
• The grant aligns management's interests with shareholder value, as the options' value is tied to the company's stock performance.

Negatives

• The future exercise of these options could lead to a minor dilutive effect on existing shareholders, although this is a standard aspect of equity compensation.

Risks

• The value of the stock options is subject to the future market price fluctuations of Personalis, Inc.'s common stock.
• If the stock price does not exceed the exercise price of $1.61, the options may not hold significant value.

Future Outlook

The vesting of performance-based stock options suggests that Personalis, Inc. has met a specific reimbursement milestone, which could imply positive progress in its operational or financial objectives. This aligns executive incentives with future company performance.

Industry Context

StockSavvy.ai notes that performance-based stock option grants are a common form of executive compensation in the biotechnology and genomics sectors. This practice aims to incentivize management to achieve specific operational or financial targets, thereby aligning their interests with long-term shareholder value creation. The satisfaction of a reimbursement milestone is a positive indicator within the industry, suggesting progress in product development or commercialization efforts.

Comparison to Industry Standards

• The grant of performance-based stock options to a Chief Medical Officer is a standard compensation practice across the biotechnology and healthcare industries, similar to companies like Illumina or Guardant Health, which frequently use equity incentives to attract and retain key talent.
• The vesting upon a 'specified reimbursement milestone' is a common performance condition, reflecting a focus on achieving commercial or clinical development targets, comparable to milestones seen in drug development or diagnostic test commercialization projects at peer companies.

Stakeholder Impact

• Shareholders: Potential for minor dilution if options are exercised, but also benefit from management incentives tied to company performance and milestone achievement.
• Employees: Reflects standard executive compensation practices, potentially influencing morale and retention of key personnel.

Next Steps

• Richard Chen may choose to exercise these options at any time between February 23, 2026, and March 15, 2034, subject to market conditions and personal financial planning.

Key Dates

Keywords

Personalis, PSNL, Richard Chen, stock options, insider transaction, executive compensation, Form 4, performance milestone, biotechnology, genomics